These materials are based on tumor-specific nanoplatforms, which are the liposomal (SGT53-01 and SGT-94) or cyclodextrin-based nanoparticular (CALAA-01) systems decorated with a target ligand of transferrin receptors in the tumor cells. This evidence concerns the gene TFRC and neoplasm.